<DOC>
	<DOC>NCT00239252</DOC>
	<brief_summary>Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.</brief_summary>
	<brief_title>Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Hepatitis C patients (high titer, genotype1) Patients with autoimmune disorder Patients with negative HBs antigen Patients with hepatic cirrhosis, hepatic failure and hepatic cancer Patients with depression or psychoneurotic disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Interferon alfacon-1</keyword>
	<keyword>Virus disease</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>